Advertisement

U.S. markets open in 1 hour 43 minutes

S&P Futures
4,699.00
+14.00(+0.30%)
Dow Futures
35,808.00
+95.00(+0.27%)
Nasdaq Futures
16,374.75
+56.75(+0.35%)
Russell 2000 Futures
2,269.80
+15.90(+0.71%)
Crude Oil
72.21
+0.16(+0.22%)
Gold
1,785.90
+1.20(+0.07%)

Advertisement

ResMed Inc. (RMD)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

265.91

+5.61

(+2.16%)

At close: 04:00PM EST

265.91

0.00

(0.00%)

After hours:

04:15PM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Williams %R

View all chart patterns

Performance Outlook

Previous Close	260.30
Open	263.08
Bid	0.00 x 900
Ask	266.66 x 1100
Day's Range	262.35 - 266.93
52 Week Range	179.37 - 301.34
Volume	375,471
Avg. Volume	564,942

Market Cap	38.749B
Beta (5Y Monthly)	0.31
PE Ratio (TTM)	77.93
EPS (TTM)	3.41
Earnings Date	Jan 26, 2022 - Jan 31, 2022
Forward Dividend & Yield	1.68 (0.65%)
Ex-Dividend Date	Nov 09, 2021
1y Target Est	265.83

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-22% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for RMD

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

ResMed Inc.
RMD: Raising target price to $269.00RESMED INC has an Investment Rating of HOLD; a target price of $269.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
Rating
Fair Value
Economic Moat
6 days agoArgus Research

All

News

Press Releases

Research Reports

Simply Wall St.
Is Weakness In ResMed Inc. (NYSE:RMD) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at ResMed's (NYSE:RMD) recent performance, when its stock has declined 13% over...
Zacks
Here's Why You Should Retain ResMed (RMD) Stock for Now
Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.
GlobeNewswire
ResMed Elects Health Tech Leaders Desney Tan and John Hernandez to Its Board of Directors
Desney Tan Desney Tan, ResMed board director John Hernandez, ResMed board director John Hernandez, ResMed board director Tan is vice president and managing director of Microsoft’s Health and Life Science R&D Hernandez is Google’s head of clinical research, health economics, and outcomes researchBoth leaders’ digital health experience at world-leading tech firms can help oversee ResMed’s strategy to improve 250 million lives in 2025ResMed’s board increases from eight to ten directors SAN DIEGO, N